We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Arsanis

News List

Arsanis and X4 Pharmaceuticals Announce Merger americanpharmaceuticalreview
November 28, 2018
Arsanis and privately-held X4 Pharmaceuticals have entered into a definitive merger agreement under which X4 Pharmaceuticals is expected to merge with a wholly-owned subsidiary .....
Arsanis Granted Key Patents for ASN100 Covering Cross-Neutralizing S. aureus Toxin Antibodies biospace
March 15, 2018
Arsanis, Inc. today announced that the United States Patent and Trademark Office ("USPTO") issued U.S.
Arsanis and Adimab Enter Into License Agreement to Target Respiratory Syncytial Virus (RSV) With Mon americanpharmaceuticalreview
February 28, 2017
Arsanis, Inc., a clinical-stage biopharmaceutical company developing targeted monoclonal antibodies for pre-emptive and post-infection treatment of serious infectious diseases,